早期和晚期克罗恩病 (LOVE-CD) 的vedolizumab:一个第四阶段的开放标签队列研究
Geert R D'Haens1, Mark Löwenberg1, Filip Baert2
1Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
The lancet. Gastroenterology & hepatology
|October 30, 2025
概括
维多利祖马布对于早期克罗恩病比晚期疾病更有效,更安全. 这种生物疗法为以前没有使用先进治疗的早期克罗恩病患者提供了有利的选择.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 临床治疗学 临床治疗学
背景情况:
- 维多利祖马布在克罗恩病缓解方面表现出有效性.
- 有限的前性数据存在于vedolizumab在克罗恩氏病早期的有效性.
- 这项研究评估了vedolizumab在早期与晚期活跃克罗恩病中的作用.
研究的目的:
- 评估vedolizumab在一年内在早期和晚期克罗恩病中诱导临床,内镜和组织学缓解的能力.
- 在不同患者群体中比较vedolizumab的疗效和安全性.
- 提供关于在克罗恩氏病早期使用vedolizumab的前性数据.
主要方法:
- 第四阶段,开放标签,多中心队列研究.
- 患有中度至重度克罗恩病 (CDAI 220-450) 的成年患者被分为早期 (诊断<2年,未经治疗) 和晚期 (诊断>2年,先前先进治疗) 组.
- 患者在52周内每8周内静脉注射300毫克vedolizumab;临床 (CDAI ≤150) 和内镜 (SES-CD <4) 缓解是26周和52周的主要终点.
主要成果:
- 26周和52周的临床和内镜缓解在早期克罗恩病患者中的31.4%和晚期克罗恩病患者中的8.6% (差异为22.8%) 实现.
- 与晚期 (26.4%) 组相比,克罗恩病早期组 (3.5%) 的严重不良事件显着较低.
- 具体的严重不良事件包括感染,手术,肠道阻塞,克罗恩氏病恶化和恶性瘤,在晚期组中更为频繁.
结论:
- 与晚期疾病患者相比,维多利祖马布治疗在早期克罗恩病患者中显示出更高的安全性和有效性.
- 维多利祖马布对于早期克罗恩病的生物无知患者来说是一个潜在的有利的治疗选择.
- 这些发现支持在克罗恩病管理中考虑使用vedolizumab进行早期干预.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
Inflammatory Bowel Disease III: Crohn's Disease
35
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
35


